Minerva Neurosciences Inc (NERV) : Cormorant Asset Management scooped up 607,903 additional shares in Minerva Neurosciences Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 1,752,946 shares of Minerva Neurosciences Inc which is valued at $20,421,821.Minerva Neurosciences Inc makes up approximately 2.60% of Cormorant Asset Management’s portfolio.
Other Hedge Funds, Including , D.a. Davidson sold out all of its stake in NERV during the most recent quarter. The investment firm sold 133,460 shares of NERV which is valued $1,554,809.Tower Research Capital (trc) reduced its stake in NERV by selling 500 shares or 71.43% in the most recent quarter. The Hedge Fund company now holds 200 shares of NERV which is valued at $2,330. Eam Investors added NERV to its portfolio by purchasing 197,025 company shares during the most recent quarter which is valued at $2,307,163. Minerva Neurosciences Inc makes up approx 0.32% of Eam Investors’s portfolio. Monashee Investment Management added NERV to its portfolio by purchasing 43,000 company shares during the most recent quarter which is valued at $473,860. Minerva Neurosciences Inc makes up approx 0.72% of Monashee Investment Management’s portfolio. Clarivest Asset Management added NERV to its portfolio by purchasing 26,100 company shares during the most recent quarter which is valued at $289,710. Minerva Neurosciences Inc makes up approx 0.01% of Clarivest Asset Management’s portfolio.
Minerva Neurosciences Inc opened for trading at $12.17 and hit $12.39 on the upside on Thursday, eventually ending the session at $12.35, with a gain of 1.06% or 0.13 points. The heightened volatility saw the trading volume jump to 1,48,709 shares. Company has a market cap of $430 M.
On the company’s financial health, Minerva Neurosciences Inc reported $-0.18 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.30.During the same quarter in the previous year, the company posted $-0.27 EPS.
Minerva Neurosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. Its lead product candidate is MIN-101 a compound for the potential treatment of patients with schizophrenia. Its product pipeline also includes MIN-117 MIN-202 and MIN-301. MIN-101 is a compound it is developing for the treatment of patients with schizophrenia. MIN-117 is a compound for the potential treatment of patients suffering from major depressive disorder (MDD). MIN-202 is a selective orexin 2 receptor antagonist it is developing in collaboration with Janssen for the treatment of insomnia. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein for the treatment of Parkinson’s disease.